ClinicalTrials.gg
CompletedNCT00301366STAMPUpdated Aug 19, 2014Results posted

The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency

A Phase 3 interventional study of alpha-1 proteinase inhibitor (human) in Alpha 1-Antitrypsin Deficiency, sponsored by Grifols Therapeutics LLC. Completed at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-19.

Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
38
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency — 2 open to participants now, 2 under way, 1 of them phase 3. alpha 1-Antitrypsin · alpha 1-Antitrypsin Deficiency.

Enrollment
9th of 25
38 · median 30
Started
2006
with 3 others
Phase 3
7 of 25
1 open now
Registered
4th of 25
by date
Lead sponsor
10 of 25
Grifols Therapeutics LLC

Among the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, this one is the 9th largest by enrollment, is one of 4 that started in 2006, is one of 7 in phase 3, and was the 4th registered.

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Open to participants now

2 of the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About alpha 1-Antitrypsin

alpha 1-Antitrypsin: first FDA approval 1987 (prolastin,prolastin-c,prolastin-c liquid), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, or all of them as a file.
02

Study summary

The purpose of this clinical study is to assess the safety and tolerability of Alpha-1 MP in adult Alpha1-antitrypsin deficient patients.

Read the detailed description

The objective of this clinical trial (STAMP: Safety and Tolerability of Alpha-1 Modified Process) is to study the safety and tolerability of Alpha-1 MP in adult Alpha 1-antitrypsin deficient subjects as reported over 20 weeks of therapy. The primary objective is to describe the nature and frequency of treatment-emergent adverse events with "treatment-emergent" defined as any adverse event occurring after the start of the first study drug infusion.

03

Conditions studied

  • Alpha 1-Antitrypsin Deficiency

Keywords

  • alpha 1-Antitrypsin Deficiency
  • alpha 1-Antitrypsin
  • pulmonary emphysema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of congenital Alpha1-antitrypsin deficiency
  • Documented (FEV1 ) between 20% - 80% of predicted value within last 6 months.
  • Signed written prior to initiation of any study related procedures.

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant, breast feeding, or if of , unwilling to practice adequate throughout the study
  • Use of systemic within the 2 weeks prior to receiving study treatment (this does not include the use of inhaled steroids used on a routine or as needed basis).
  • Subjects who have had exacerbations of their disease within one month of trial entry
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Alpha-1 Proteinase Inhibitor (Human), modified process

    Study the safety and tolerability of weekly infusions of Alpha-1 Proteinase Inhibitor (Human), modified process (Alpha-1 MP, 60 mg/kg) over 20 weeks of therapy in adult Alpha-1 antitrypsin deficient subjects.

    Drug: alpha-1 proteinase inhibitor (human)

Interventions

06

What researchers measure

Primary outcomes

  1. Treatment-emergent Adverse Events (TEAEs) Defined as Any Adverse Event (AE) Occurring During or After the Start of the First Study Drug Infusion.

    An adverse event is any untoward medical occurrence in a subject or clinical investigation subject administered with a pharmaceutical product. The adverse event does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the medicinal product.

    Time frame: 24 weeks

07

Results

Posted Aug 19, 2014

Participant flow

First-subject-first-dose was 12 June 2006, last-subject-last-visit was 20 March 2007. The study was performed in 10 clinical sites, 8 sites in the United States and 2 sites in the United Kingdom.

Participant flow — Overall Study
MilestoneAlpha-1MP Treatment Group
Started38
Completed37
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryTreatment-emergent Adverse Events (TEAEs) Defined as Any Adverse Event (AE) Occurring During or After the Start of the First Study Drug Infusion.

An adverse event is any untoward medical occurrence in a subject or clinical investigation subject administered with a pharmaceutical product. The adverse event does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the medicinal product.

Time frame:
24 weeks
Reported as:
Number · Participants
Treatment-emergent Adverse Events (TEAEs) Defined as Any Adverse Event (AE) Occurring During or After the Start of the First Study Drug Infusion.
ParticipantsAlpha-1 MP Treatment Group
Number of Participants Analyzed38
Subjects experiencing TEAEs26
Subjects with TEAEs <24 hrs. of A-1 MP infusion17
Alpha-1 MP subjects with ≥1 drug-related TEAE5

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alpha-1MP Treatment Group—2/38 (5.3%)26/38 (68.4%)
Most frequent serious events
Most frequent serious events
EventAlpha-1MP Treatment Group
PneumoniaInfections and infestations1/38
RashSkin and subcutaneous tissue disorders1/38
Most frequent other events
Showing 10 of 18
Most frequent other events
EventAlpha-1MP Treatment Group
NauseaGastrointestinal disorders6/38
Upper respiratory tract infectionInfections and infestations6/38
Urinary tract infectionInfections and infestations5/38
Chest painGeneral disorders4/38
Influenza like illnessGeneral disorders2/38
ChillsGeneral disorders2/38
NasopharyngitisInfections and infestations2/38
Oral candidiasisInfections and infestations2/38
ArthralgiaMusculoskeletal and connective tissue disorders2/38
Back painMusculoskeletal and connective tissue disorders2/38

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Entered Study
<=18 years0
Between 18 and 65 years32
>=65 years6
Age, Continuous
Age, Continuous(years)Entered Study
Mean53.4 ± 8.63
Sex: Female, Male
Sex: Female, Male(Participants)Entered Study
Female15
Male23
Region of Enrollment
Region of Enrollment(participants)Entered Study
United States35
United Kingdom3
08

Study locations

10 sites
  • National Jewish Medical and Research Center
    Denver, Colorado 80206, United States
  • University of Florida College of Medicine
    Gainesville, Florida 32610-0225, United States
  • University of Miami School of Medicine
    Miami, Florida 33101, United States
  • St Lukes-Roosevelt Hospital Center, New York
    New York, New York 10019, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44122, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • University of Texas Health Center at Tyler
    Tyler, Texas 75708-3154, United States
  • University of Cambridge - Cambridge Institute for Medical Research
    Cambridge, England CB2 2XY, United Kingdom
  • University Teaching Hospital of Edinburgh
    Edinburgh, Scotland EH8 9AG, United Kingdom
09

References and documents

Publications

  • Wewers MD, Casolaro MA, Sellers SE, Swayze SC, McPhaul KM, Wittes JT, Crystal RG. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med. 1987 Apr 23;316(17):1055-62. doi: 10.1056/NEJM198704233161704. PubMed 3494198 ↗
  • Gadek JE, Klein HG, Holland PV, Crystal RG. Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest. 1981 Nov;68(5):1158-65. doi: 10.1172/jci110360. PubMed 7028785 ↗
  • Gadek JE, Fells GA, Zimmerman RL, Rennard SI, Crystal RG. Antielastases of the human alveolar structures. Implications for the protease-antiprotease theory of emphysema. J Clin Invest. 1981 Oct;68(4):889-98. doi: 10.1172/jci110344. PubMed 6169740 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of Mar 2007 and a completion of Mar 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 7 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2006
First posted
Mar 10, 2006
Start
Jun 2006
Primary completionActual
Mar 2007
CompletionActual
Mar 2007
Results first posted
Aug 19, 2014
Last update
Aug 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00301366
Responsible party
Sponsor
First posted
Mar 10, 2006
Start date
Jun 2006
Primary completion
Mar 2007
Completion
Mar 2007
Results posted
Aug 19, 2014
Last update
Aug 19, 2014

Study contacts

Kim Hanna, MSc
study director · Grifols Therapeutics LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha 1-Antitrypsin

Start the discussion